Literature DB >> 33372366

Safety of Andrographis paniculata: A systematic review and meta-analysis.

Wiwan Worakunphanich1,2, Montarat Thavorncharoensap3,4, Sitaporn Youngkong3,4, Kunlawat Thadanipon5, Ammarin Thakkinstian3,5.   

Abstract

PURPOSE: Andrographis paniculata is one of the commonly used herbal medicines worldwide. Nevertheless, evidences on adverse events (AEs) associated with Andrographis paniculata are very limited. This systematic review and meta-analysis was conducted to estimate and to compare the AE incidence of oral monotherapy Andrographis paniculata with others among patients with upper respiratory tract infection, noninfective diarrhea, and autoimmune disease.
METHODS: Systematic search was performed through six databases from inception until August 2018. Randomized controlled trial (RCT), cohort, or intensive monitoring of AEs was eligible for review if AE incidence was examined. The incidence of AEs was, then, pooled across studies using meta-analysis.
RESULTS: Ten RCTs and 3 intensive monitoring studies were included. Incidence of serious AEs was very rare with the pooled incidence (95% CI) from RCTs of 0.02 per 1000 patients (0.0-0.5). However, the incidence of nonserious AEs was considered very common with the pooled incidence (95% CI) from RCTs of 102.6 per 1000 patients (10.7-256.1), and the pooled incidence (95% CI) from intensive monitoring of 34.2 per 1000 patients (0.0-229.6). The most common nonserious AEs were related to gastrointestinal disorder, and skin and subcutaneous disorder system.
CONCLUSIONS: Like other medicine, Andrographis paniculata can cause some AEs. However, it may be generally safe. Nevertheless, prospective patients who plan to use Andrographis paniculata should be thoroughly advised and closely monitored for common AEs. Due to the increasing use of Andrographis paniculata worldwide, larger studies with adequate methodological quality are warranted to monitor the safety of such product.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  Andrographis paniculata; adverse event; pharmacovigilance; safety

Year:  2021        PMID: 33372366     DOI: 10.1002/pds.5190

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.

Authors:  Mikayel Narimanyan; Kristina Jamalyan; Anna Balyan; Anders Barth; Staffan Palm; Georg Wikman; Alexander Panossian
Journal:  J Tradit Complement Med       Date:  2021-06-11

2.  Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised patients with mild coronavirus disease 2019: A retrospective cohort study.

Authors:  Jeeranan Tanwettiyanont; Napacha Piriyachananusorn; Lilit Sangsoi; Benjawan Boonsong; Chamlong Sunpapoa; Patcharawan Tanamatayarat; Nat Na-Ek; Sukrit Kanchanasurakit
Journal:  Front Med (Lausanne)       Date:  2022-08-10

3.  Pharmacokinetics and Metabolomic Profiling of Metformin and Andrographis paniculata: A Protocol for a Crossover Randomised Controlled Trial.

Authors:  Khim Boon Tee; Luqman Ibrahim; Najihah Mohd Hashim; Mohd Zuwairi Saiman; Zaril Harza Zakaria; Hasniza Zaman Huri
Journal:  J Clin Med       Date:  2022-07-06       Impact factor: 4.964

4.  Perspective: repurposed drugs for COVID-19.

Authors:  Kesara Na-Bangchang; Supatra Porasuphatana; Juntra Karbwang
Journal:  Arch Med Sci       Date:  2022-08-30       Impact factor: 3.707

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.